Phase 1 study of human atrial natriuretic peptide during perioperative period for completely resected colorectal cancer

Phase 1 study of human atrial natriuretic peptide during perioperative period for completely resected colorectal cancer - Phase 1 study of hANP for colorectal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025877

Enrollment

Registered

2017-02-01

Start date

2017-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

hANP administration (0.025 maicrog/kg/min) is started at 2 hours before operation. hANP administration is continued for 3 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically or clinically proven completely resectable colorectal cancer 2. PS(ECOG):0-2 3. Adequate organ functions judged by laboratory tests 4. Written informed consent

Exclusion criteria

Exclusion criteria: 1. previously hANP therapy 2. Participating the other clinical trial 3. obstruction of gastrointestinal tract 4. Active infectious disease 5. Uncontrollable severe comorbidities 6. Severe allergic history 7. Women during pregnancy or breast-feeding 8. Severe hypotension or cardiogenic shock 9. History of right ventricular infarction 10. hypovolemia 11. Other conditions judged ineligible by physician

Design outcomes

Primary

Measure	Time frame
Safety	—

Countries

Japan

Contacts

Public ContactHidekazu Takahashi

Osaka University Graduate School of Medicine Depertment of gastroenterological surgery

htakahashi@gesurg.med.osaka-u.ac.jp06-6879-3251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026